Does Spravato Help with Anxiety? What to Expect

Living with chronic anxiety is deeply exhausting. When your nervous system is stuck in persistent alarm—causing racing thoughts, chest tightness, restlessness, and sudden panic—daily life becomes exhausting. For many adults, standard treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) and benzodiazepines fail to provide lasting relief or carry side effects like emotional blunting and dependence.

As innovative interventional treatments transform psychiatric medicine, patients frequently visit Options Psychiatry in Reading, PA asking: Does Spravato help with anxiety?

To determine if Spravato is appropriate for you, explore how esketamine differs from traditional antidepressants, the role of off-label clinical practice, and our treatment protocols under board-certified psychiatrist Dr. Cyntrell Crawford.

Understanding Spravato (Esketamine): FDA Approval vs. Off-Label Anxiety Use

Spravato is the commercial brand name for esketamine, the S-enantiomer of ketamine. In 2019, the U.S. Food and Drug Administration (FDA) approved Spravato for adults with Treatment-Resistant Depression (TRD)—defined as depression that has failed to improve after trying at least two different antidepressant medications. In 2020, the FDA approved Spravato for Major Depressive Disorder with acute suicidal thoughts.

Where does anxiety fit into this clinical framework?

In clinical psychiatry, mood and anxiety disorders frequently co-occur. Research indicates that between 60% and 75% of adults diagnosed with depression also experience clinically significant anxiety, including Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, or Panic Disorder. Psychiatrists classify this condition as anxious depression. Individuals with anxious depression face greater impairment and medication resistance.

While the pharmaceutical manufacturer has not sought an isolated FDA approval exclusively for GAD, psychiatrists regularly prescribe Spravato for anxious depression. Clinicians also utilize evidence-based off-label prescribing for refractory anxiety when first-line medications fail. Off-label prescribing is a lawful, established psychiatric practice where an FDA-approved drug is prescribed based on peer-reviewed clinical research and neurobiological rationale.

The Neurobiology: How Spravato Works in the Anxious Brain

The reason Spravato succeeds where traditional medications often fail lies in its unique neurochemical target. Traditional medications and esketamine utilize fundamentally different biological pathways:

1. Moving Beyond the Monoamine Hypothesis

For decades, psychiatry focused on the monoamine hypothesis, assuming anxiety stemmed solely from serotonin or norepinephrine deficits. Medications like Lexapro, Zoloft, or Effexor attempt to boost these neurotransmitters slowly, often requiring 4 to 8 weeks, with roughly one-third of patients never achieving remission. Learn more in our article on whether anxiety gets worse over time.

2. NMDA Receptor Antagonism & Glutamate Signaling

Spravato bypasses monoamines entirely. It acts as an antagonist at N-methyl-D-aspartate (NMDA) receptors on GABAergic interneurons. By temporarily blocking these receptors, Spravato triggers a controlled surge of glutamate—the brain's primary excitatory neurotransmitter responsible for synaptic plasticity and emotional regulation.

3. AMPA Activation and BDNF Synaptogenesis

This transient glutamate burst stimulates post-synaptic AMPA receptors, prompting the release of Brain-Derived Neurotrophic Factor (BDNF). BDNF acts as molecular fertilizer for neurons, stimulating rapid synaptogenesis—the physical repair and regrowth of dendritic spines that chronic stress, elevated cortisol, and anxiety have damaged in the prefrontal cortex and hippocampus.

4. Calming the Amygdala and Resetting the Default Mode Network (DMN)

Chronic anxiety causes functional dysregulation in two critical brain regions: the amygdala (the fear alarm center) and the Default Mode Network (DMN) (the neural network responsible for rumination and catastrophic self-talk). Neuroimaging demonstrates that Spravato rapidly quiets DMN hyper-connectivity while restoring prefrontal cortical oversight of the amygdala, breaking entrenched panic loops within hours.

Types of Anxiety That May Benefit from Spravato

Because Spravato rebuilds neural pathways and dampens fear reactivity, clinical benefits appear across several anxiety disorders:

• Comorbid Anxious Depression: For patients whose depression is accompanied by psychic agitation, motor restlessness, and panic, Spravato frequently produces rapid, concurrent reductions in both mood and anxiety scales.
• Treatment-Resistant Generalized Anxiety Disorder (GAD): Patients who have tried multiple SSRIs, SNRIs, and buspirone without relief often find that esketamine significantly decreases constant muscle tension, racing thoughts, and persistent dread.
• Social Anxiety Disorder (SAD): Severe social phobia stems from rigid fear conditioning. By enhancing neuroplasticity, esketamine helps soften threat overestimation and facilitates social comfort.
• Trauma-Related Anxiety and PTSD: Chronic psychological trauma compromises cognitive processing and hyper-activates the nervous system—a reality we explore in our guide on whether PTSD causes memory loss. Spravato helps calm trauma-induced hyperarousal and panic.

Spravato vs. Traditional Anxiety Treatments: A Clinical Comparison

Understanding where Spravato fits alongside existing psychiatric treatments helps clarify its unique therapeutic value:

Spravato delivers the rapid relief associated with acute sedatives, but achieves this by repairing neural pathways without dependency risks. Learn more in our comparison of TMS Therapy vs. Spravato.

What to Expect During a Spravato Treatment Session

Because Spravato is regulated under an FDA Risk Evaluation and Mitigation Strategy (REMS), it is never dispensed at a retail pharmacy for home use. Every session occurs in a certified psychiatric center under medical supervision.

Here is what patients experience during a Spravato session at our Reading, PA mental health clinic:

1. Baseline Assessment & Suite Preparation

Upon arrival, clinical staff check your baseline vital signs. You are escorted into a quiet, private comfort suite with dimmed lighting and reclining seating designed to minimize sensory stimulation.

2. Guided Self-Administration

Under medical supervision, you self-administer the nasal spray device (delivering 56 mg or 84 mg across two or three devices spaced five minutes apart), guided by our clinical team.

3. Two-Hour In-Office Observation

You rest comfortably during the mandatory two-hour monitoring period while peak therapeutic effects occur. Patients experience deep relaxation and mild perceptual softening that peaks at 40 minutes and resolves prior to departure.

4. Safe Discharge & Timeline

After vitals are rechecked and alertness is confirmed, you are discharged to a designated driver (no driving until the next morning). The standard protocol includes two sessions weekly for weeks 1–4, one weekly for weeks 5–8, and maintenance thereafter. Learn more in our guide on how to get evaluated for Spravato therapy.

Who Is a Good Candidate for Spravato?

Spravato is intended for moderate to severe psychiatric symptoms that have resisted conventional care. You may be an ideal candidate if:

• You are an adult aged 18+ diagnosed with Major Depressive Disorder or treatment-resistant depression with prominent anxiety or panic features.
• You have tried at least two different antidepressant medications without achieving adequate relief.
• You seek a rapid-acting intervention that avoids daily sedative dependence.
• You can commit to the in-office treatment protocol and arrange safe transportation home.

Medical Contraindications: Spravato is not clinically appropriate for individuals with aneurysmal vascular disease, arteriovenous malformations, history of intracerebral hemorrhage, uncontrolled severe hypertension, or current pregnancy/breastfeeding. A comprehensive psychiatric evaluation with Dr. Cyntrell Crawford ensures all medical factors are safely assessed.

Does Health Insurance Cover Spravato for Anxiety?

Insurance coverage depends on formal diagnostic coding. Because Spravato holds official FDA approval for Treatment-Resistant Depression (TRD), commercial insurers and Medicare cover the medication and observation when TRD criteria are met (failure of 2+ antidepressants).

Because most individuals with severe anxiety also meet clinical criteria for depression, our intake team helps verify eligibility under TRD guidelines, securing coverage while alleviating anxiety. For complete details, see our guide on whether Spravato is covered by insurance.

Comprehensive Mental Health Care at Options Psychiatry in Reading, PA

Lasting emotional stability is best achieved through integrated care. At Options Psychiatry, we combine Spravato with comprehensive psychiatric support:

• Integrative Psychotherapy: Following Spravato, the brain enters a window of heightened neuroplasticity. Partnering with counselors, such as through our community partners at Pennsylvania Counseling Services, helps reinforce new coping patterns and emotional resilience.
• Expert Medication Management: Our psychiatric team provides ongoing medication management to ensure your oral medications complement your Spravato protocol.
• Transcranial Magnetic Stimulation (TMS): For patients who prefer a non-pharmacological neuromodulation option, TMS Therapy uses magnetic pulses to stimulate prefrontal networks. Learn more at our specialized TMS therapy clinic in Reading, PA.
• Somatic and Lifestyle Strategies: We assist patients in establishing restorative sleep routines, breathwork grounding, and stress-reduction habits that maintain autonomic stability.

Frequently Asked Questions About Spravato and Anxiety

1. Is Spravato FDA-approved for anxiety disorders?

No. Spravato is FDA-approved for Treatment-Resistant Depression (TRD) and Major Depressive Disorder with acute suicidal ideation. However, because over 70% of TRD patients suffer from severe anxiety, psychiatrists frequently prescribe Spravato off-label for refractory anxiety, and patients consistently experience significant anxiety reduction during treatment.

2. How fast does Spravato reduce anxiety symptoms?

Unlike standard SSRIs and SNRIs that require 4 to 8 weeks, Spravato targets glutamate receptors to stimulate rapid synaptogenesis. Many patients report marked reductions in physical panic and racing thoughts within 4 to 24 hours of their initial sessions, with cumulative benefits building over 8 weeks.

3. Can Spravato make anxiety worse during or after treatment?

During the first 45 minutes of a session, patients may experience mild, transient dissociative sensations. In our calming clinical suites under continuous medical supervision, these sensations are peaceful and resolve within the mandatory 2-hour observation window. Overall, Spravato substantially decreases baseline anxiety over time.

4. Is Spravato therapy covered by insurance for anxiety?

Insurers cover Spravato when prescribed for Treatment-Resistant Depression (failing two or more antidepressants). Because most individuals with severe anxiety also meet clinical criteria for TRD, patients routinely qualify for insurance coverage while achieving major anxiety symptom relief.

5. How does Spravato differ from IV Ketamine infusions for anxiety?

Spravato contains esketamine nasal spray, which is FDA-approved and covered by most major health insurance plans in certified REMS clinics. In contrast, IV ketamine infusions remain off-label for psychiatric conditions and are rarely covered by insurance, requiring thousands in out-of-pocket expenses.

6. Can I take Spravato if I am already taking anxiety medications like SSRIs or Buspar?

Yes. Spravato is FDA-indicated to be taken alongside an oral antidepressant. Patients generally maintain their current maintenance medications, though high-dose sedatives or benzodiazepines may be adjusted on treatment days to ensure optimal neuroplastic benefits.

7. How do I get evaluated for Spravato treatment at Options Psychiatry in Reading, PA?

Contact Options Psychiatry in Reading, PA by calling (610) 741-6567 or submitting our online confidential form. Our clinical team will evaluate your treatment history, confirm insurance eligibility, and create a personalized recovery roadmap.